Figures
In their January editorial, the PLOS Medicine Editors discuss a paper which shows discrepancies between internal company documents and published reports of industry-sponsored trials. However, a new initiative from the European Medicines Agency (EMA) which aims to ensure that clinical trial data are released once the marketing authorization process has ended may go some way to addressing concerns over transparency of clinical trial findings. With this initiative planned to start in January 2014, the editors argue that EMA will need to hold a firm course during 2013 while the details of the initiative are ironed out.
Image Credit: Mark Tighe at Flickr
Citation: (2013) PLoS Medicine Issue Image | Vol. 10(1) January 2013. PLoS Med 10(1): ev10.i01. https://doi.org/10.1371/image.pmed.v10.i01
Published: January 29, 2013
Copyright: © 2013 Tighe. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In their January editorial, the PLOS Medicine Editors discuss a paper which shows discrepancies between internal company documents and published reports of industry-sponsored trials. However, a new initiative from the European Medicines Agency (EMA) which aims to ensure that clinical trial data are released once the marketing authorization process has ended may go some way to addressing concerns over transparency of clinical trial findings. With this initiative planned to start in January 2014, the editors argue that EMA will need to hold a firm course during 2013 while the details of the initiative are ironed out.
Image Credit: Mark Tighe at Flickr